Loading organizations...
§ Private Profile · Cambridge, United Kingdom
Qureight is a technology company.
Qureight is focused on advancing the understanding of lung and heart diseases through AI-powered data curation and imaging analysis, aimed at accelerating drug development and clinical trials.
Qureight has raised $10.0M across 2 funding rounds.
Qureight has raised $10.0M in total across 2 funding rounds.
Qureight has raised $10.0M across 2 funding rounds. Most recently, it raised $8.0M Series A in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2024 | $8M Series A | Lucy Bloomfield | Credo Ventures, Playfair Capital, Techstart Ventures, Calum Forsyth, Will Brooks, Will Martin, Ascension, Cambridge Angels, Christopher Smith, Malcolm King, Meltwind, Gabriele Papievyte | Announced |
| Jan 1, 2022 | $2M Seed | Playfair Capital | Ascension, Cambridge Angels, Meltwind | Announced |
Qureight is a Cambridge, UK-based technology company founded in 2018 that builds an AI-powered, cloud-based Core Imaging Platform for data curation and analytics in clinical trials focused on lung and heart diseases.[1][2][3][4][6] It serves pharmaceutical companies, contract research organizations (CROs), hospitals, and biopharma partners by analyzing imaging, clinical data, and biomarkers to accelerate drug development, identify endpoints, create synthetic control arms, and improve patient selection—addressing high failure rates and long timelines in trials for conditions like idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).[1][2][4][5][6] The vendor-agnostic platform is GDPR, HIPAA, NHS Digital, ISO 13485, and ISO 27001 compliant, with its flagship AI Lung suite of 3D imaging tools now used as endpoints in global phase 2 and 3 trials, outperforming expert clinicians in diagnosis and tracking.[1][2][5][6] Qureight has raised £2.5 million, employs 1-10 people, and shows growth through partnerships like AstraZeneca, Vicore, Insilico Medicine, and Rein Therapeutics.[3][4][6]
Qureight was founded in 2018 by doctors, scientists, and engineers in Cambridge, UK, led by co-founder and CEO Dr. Muhunthan Thillai, a pulmonologist specializing in complex lung diseases like fibrosis.[1][2][4] The idea emerged from clinical expertise in lung and heart diseases, combined with AI and data analytics needs to unlock anonymized clinical data's value—partnering with healthcare bodies, software developers, drug companies, and academics to annotate, analyze imaging, and test machine learning algorithms.[3][4] Early traction came via the Cambridge Judge Business School's Accelerate program (Cohort 15 alumni), seed funding of £1.5 million (part of £2.5 million total), and collaborations like AstraZeneca for respiratory research, building on Thillai's role as past Imaging Chair for the European Respiratory Society and election to the Fleischner Society.[2][3][4] Key team members include a CFO with machine learning and computer vision research in lung biomarkers, a CTO with big data experience from Autonomy and HP, and a finance lead with biotech scaling background.[4]
Qureight rides the AI-in-healthcare wave, leveraging machine learning on imaging/clinical data to tackle inefficient drug development in lung/heart diseases—markets larger than all cancers combined by development time, cost, and reimbursement spend.[3][6] Timing aligns with rising biopharma demand for real-world evidence, synthetic controls, and non-invasive endpoints amid regulatory pushes for faster approvals and post-COVID respiratory focus.[2][5][6] Favorable forces include abundant anonymized datasets, AI advancements in biomarkers, and partnerships accelerating trials (e.g., IPF/PH therapies from Rein Therapeutics, Vicore).[2][3][6] It influences the ecosystem by enabling pharma like AstraZeneca to refine patient selection/outcomes, reducing trial failures, and validating AI as standard in rare disease studies.[4][6]
Qureight is poised to expand its AI Lung platform into more phase 3 trials and new indications, building on 2025 collaborations like Rein Therapeutics' IPF phase 2 integration.[3] Trends like AI-driven synthetic arms, multimodal data (imaging + biomarkers), and regulatory acceptance of digital endpoints will propel growth, potentially scaling via larger funding or acquisitions amid biopharma's $100B+ respiratory pipeline needs.[2][6] Its influence may evolve from niche analytics to core infrastructure for lung/heart trials, transforming data curation into a standard that speeds therapies and improves outcomes—echoing its mission to revolutionize clinical development from the frontlines of pulmonology.[1][4]
Qureight has raised $10.0M in total across 2 funding rounds.
Qureight's investors include Lucy Bloomfield, Credo Ventures, Playfair Capital, Techstart Ventures, Calum Forsyth, Will Brooks, Will Martin, Ascension, Cambridge Angels, Christopher Smith, Malcolm King, Meltwind.